New mRNA vaccine trial aims to stop genital herpes
NCT ID NCT07330440
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study is testing an mRNA vaccine designed to protect against genital herpes (HSV-2) in 144 healthy adults aged 18 to 55. The vaccine is given in different doses to people who have and have not been exposed to the virus before. The main goal is to check for side effects and see how well the vaccine triggers an immune response.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENITAL HERPES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Jishuitan Hospital
Beijing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.